en · de · es · fr · pt
melanotan-2-notes.peptides9002.com › Guide › Origins And Research Status — Practical Notes

Origins And Research Status — Practical Notes

By Editorial Desk · published 2025-11-18 · last reviewed 2025-12-24 · Guide

This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-12-24 and is reviewed periodically as new material appears.

Origins and Research Status

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.

Background and Mechanism of Melanotan-2

Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.

Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.

Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideBelongs to the melanocortin agonist family
Key substitutionsNle4 and D-Phe7Improve resistance to enzymatic degradation
Molecular formulaC50H69N15O9Approximately 1024 g/mol
Regulatory statusNot approved as a medicineDistributed as a research chemical
Common synonymsMelanotan II, MT-II, MT-2Spelling varies across sources

Chemistry and Receptor Pharmacology

Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.

Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.

Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.

Related pages on this site

Further detail

==== IR spectroscopy ==== One case study investigated the formation of gaseous intermediates in the decomposition of CCl4 in the presence of steam over La2O3 using Fourier-transform infrared spectroscopy. This experiment produced useful information about the reaction mechanism, active site orientation, and about which species compete for the active site.

== Related concepts == The concept of shelf life applies to other products besides food and drugs. Gasoline has a shelf life, although it is not normally necessary to display a sell-by date. Exceeding this time-frame will introduce harmful varnishes, etc. into equipment designed to operate with these products, i.e. a gasoline lawn mower that has not been properly winterized could incur damage that will prevent use in the spring, and require expensive servicing to the carburetor. Some glues and adhesives also have a limited storage life, and will stop working in a reliable and usable manner if their safe shelf life is exceeded. Rather different is the use of a time limit for the use of items like vouchers, gift certificates and pre-paid phone cards, so that after the displayed date the voucher etc. will no longer be valid. Bell Mobility and its parent company, BCE Inc. have been served with notice of a $100-million class-action lawsuit alleging that expiry dates on its pre-paid wireless services are illegal.

=== Freeze drying === In planning for the long-duration Apollo missions, NASA conducted extensive research into space food. One of the techniques developed in 1938 by Nestlé was freeze drying. The foods are cooked, quickly frozen, and then slowly heated in a vacuum chamber to remove the ice crystals formed by the freezing process. The final product retains 98% of its nutrition and weighs much less than before drying. The ratio of weight before and after drying depends strongly on the particular food item but a typical freeze-dried weight is 20% of the original weight. In the United States, Action Products later commercialized this technique for other foods, concentrating on snack food resulting in products like Space ice cream. Today, one of the benefits of this advancement in food preservation includes simple, nutritious meals available to disabled and otherwise homebound senior adults unable to take advantage of existing meal programs.

Sources: en.wikipedia.org

Supporting material

Reflecting the strength of the C−Hg bond, organomercury compounds are generated by many methods. Indeed, mercury adsorbs onto laboratory glassware, such that laboratories performing mercury experiments may have difficulty avoiding C−Hg bond formation. In some regards, organomercury chemistry more closely resembles organopalladium chemistry and contrasts with organocadmium compounds.

Elongation factors are part of the mechanism that synthesizes new proteins through translation in the ribosome. Transfer RNAs (tRNAs) carry the individual amino acids that become integrated into a protein sequence, and have an anticodon for the specific amino acid that they are charged with. Messenger RNA (mRNA) carries the genetic information that encodes the primary structure of a protein, and contains codons that code for each amino acid. The ribosome creates the protein chain by following the mRNA code and integrating the amino acid of an aminoacyl-tRNA (also known as a charged tRNA) to the growing polypeptide chain. There are three sites on the ribosome for tRNA binding. These are the aminoacyl/acceptor site (abbreviated A), the peptidyl site (abbreviated P), and the exit site (abbreviated E). The P-site holds the tRNA connected to the polypeptide chain being synthesized, and the A-site is the binding site for a charged tRNA with an anticodon complementary to the mRNA codon associated with the site. After binding of a charged tRNA to the A-site, a peptide bond is formed between the growing polypeptide chain on the P-site tRNA and the amino acid of the A-site tRNA, and the entire polypeptide is transferred from the P-site tRNA to the A-site tRNA. Then, in a process catalyzed by the prokaryotic elongation factor EF-G (historically known as translocase), the coordinated translocation of the tRNAs and mRNA occurs, with the P-site tRNA moving to the E-site, where it dissociates from the ribosome, and the A-site tRNA moves to take its place in the P-site.

Latin America (via IIAA). India, Pakistan, and Ceylon. The U.S. also participated in post-1945 UN initiatives for technical assistance to developing countries. Through a series of actions in 1948 and 1949, the UN's General Assembly and Economic and Social Council (ECOSOC) created the Expanded Programme of Technical Assistance (EPTA). The U.S. provided 60% of EPTA's financing. By 1955, EPTA adopted a country-led approach where the UN's TA in each country was programmed according to a plan drawn up by the receiving country in consultation with the UN. ECOSOC also created a new Technical Assistance Board, which (similarly to the United States' wartime Interdepartmental Committee) coordinated the TA being provided to low-income countries by various individual UN agencies.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan II?

It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.

Is melanotan II an approved medicine?

No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.

What do published reports describe?

Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.

Is melanotan-2 a natural hormone?

No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.

Network